Dalmau J, Dalakas M, Kolson D, Probstel A, Paul F, Zamvil S
Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200363.
PMID: 39724529
PMC: 11676263.
DOI: 10.1212/NXI.0000000000200363.
Tonev D, Momchilova A
Int J Mol Sci. 2023; 24(24).
PMID: 38139050
PMC: 10743556.
DOI: 10.3390/ijms242417223.
Engel S, Molina Galindo L, Bittner S, Zipp F, Luessi F
J Cent Nerv Syst Dis. 2022; 13:11795735211037798.
PMID: 34992484
PMC: 8725211.
DOI: 10.1177/11795735211037798.
Dohrn M, Ellrichmann G, Pjontek R, Lukas C, Panse J, Gold R
Ther Adv Neurol Disord. 2021; 14:17562864211035543.
PMID: 34377151
PMC: 8326823.
DOI: 10.1177/17562864211035543.
Nielsen A
Degener Neurol Neuromuscul Dis. 2020; 5:51-61.
PMID: 32669912
PMC: 7337155.
DOI: 10.2147/DNND.S68723.
Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes.
Bhargava P, Fitzgerald K, Venkata S, Smith M, Kornberg M, Mowry E
Ann Clin Transl Neurol. 2019; 6(1):33-45.
PMID: 30656182
PMC: 6331509.
DOI: 10.1002/acn3.676.
Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai R, Mahesri M, Gagne J, Hurley E, Tong A, Chitnis T
J Manag Care Spec Pharm. 2018; 25(1):113-121.
PMID: 30589630
PMC: 10397781.
DOI: 10.18553/jmcp.2019.25.1.113.
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
Faissner S, Gold R
CNS Drugs. 2018; 32(3):269-287.
PMID: 29600441
DOI: 10.1007/s40263-018-0488-6.
Oral Therapies for Multiple Sclerosis.
Faissner S, Gold R
Cold Spring Harb Perspect Med. 2018; 9(1).
PMID: 29500302
PMC: 6314072.
DOI: 10.1101/cshperspect.a032011.
Fumaric acid esters in the management of psoriasis.
Balak D
Psoriasis (Auckl). 2018; 5:9-23.
PMID: 29387578
PMC: 5683116.
DOI: 10.2147/PTT.S51490.
ERK Is a Critical Regulator of JC Polyomavirus Infection.
DuShane J, Wilczek M, Mayberry C, Maginnis M
J Virol. 2018; 92(7).
PMID: 29321332
PMC: 5972906.
DOI: 10.1128/JVI.01529-17.
Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.
Moss H
Eye Brain. 2017; 9:13-21.
PMID: 28721111
PMC: 5498528.
DOI: 10.2147/EB.S140481.
Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
Chaves C, Ganguly R, Ceresia C, Camac A
Mult Scler J Exp Transl Clin. 2017; 3(2):2055217317702933.
PMID: 28607757
PMC: 5408504.
DOI: 10.1177/2055217317702933.
Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.
Gieselbach R, Muller-Hansma A, Wijburg M, de Bruin-Weller M, van Oosten B, Nieuwkamp D
J Neurol. 2017; 264(6):1155-1164.
PMID: 28536921
DOI: 10.1007/s00415-017-8509-9.
Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.
Misbah S
Clin Exp Immunol. 2017; 188(3):342-352.
PMID: 28245526
PMC: 5422720.
DOI: 10.1111/cei.12948.
Infectious Complications of Novel Multiple Sclerosis Therapies.
Levin S, Kaplan T
Curr Infect Dis Rep. 2017; 19(2):7.
PMID: 28233190
DOI: 10.1007/s11908-017-0562-0.
Disease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNS.
Park S, Jeong I, Kong B, Lee J, Kim K, Lee D
PLoS One. 2016; 11(11):e0166277.
PMID: 27855220
PMC: 5113962.
DOI: 10.1371/journal.pone.0166277.
Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.
Hegen H, Auer M, Deisenhammer F
Drugs. 2016; 76(15):1421-1445.
PMID: 27653757
DOI: 10.1007/s40265-016-0639-3.
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.
Maas R, Muller-Hansma A, Esselink R, Murk J, Warnke C, Killestein J
J Neurol. 2016; 263(10):2004-21.
PMID: 27401179
PMC: 5037162.
DOI: 10.1007/s00415-016-8217-x.
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.
Fox R, Chan A, Gold R, Phillips J, Selmaj K, Chang I
Neurol Clin Pract. 2016; 6(3):220-229.
PMID: 27347439
PMC: 4909524.
DOI: 10.1212/CPJ.0000000000000238.
